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Objective: To evaluate the effects of acute exposure to high altitude and preventive
dexamethasone treatment on postural control in patients with chronic obstructive
pulmonary disease (COPD).
Methods: In this randomized, double-blind parallel-group trial, 104 lowlanders with
COPD GOLD 1-2 age 20–75 years, living near Bishkek (760 m), were randomized
to receive either dexamethasone (2 × 4 mg/day p.o.) or placebo on the day before
ascent and during a 2-day sojourn at Tuja-Ashu high altitude clinic (3100 m), Kyrgyzstan.
Postural control was assessed with a Wii Balance BoardTM at 760 m and 1 day after
arrival at 3100 m. Patients were instructed to stand immobile on both legs with eyes
open during five tests of 30 s each, while the center of pressure path length (PL) was
measured.
Results: With ascent from 760 to 3100 m the PL increased in the placebo group
from median (quartiles) 29.2 (25.8; 38.2) to 31.5 (27.3; 39.3) cm (P < 0.05); in the
dexamethasone group the corresponding increase from 28.8 (22.8; 34.5) to 29.9
(25.2; 37.0) cm was not significant (P = 0.10). The mean difference (95% CI) between
dexamethasone and placebo groups in altitude-induced changes (treatment effect)
was −0.3 (−3.2 to 2.5) cm, (P = 0.41). Multivariable regression analysis confirmed
a significant increase in PL with higher altitude (coefficient 1.6, 95% CI 0.2 to 3.1,
P = 0.031) but no effect of dexamethasone was shown (coefficient −0.2, 95% CI
−0.4 to 3.6, P = 0.925), even when controlled for several potential confounders. PL
changes were related more to antero-posterior than lateral sway. Twenty-two of 104
patients had an altitude-related increase in the antero-posterior sway velocity of >25%,
what has been associated with an increased risk of falls in previous studies.
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Conclusion: Lowlanders with COPD travelling from 760 to 3100 m revealed postural
instability 24 h after arriving at high altitude, and this was not prevented by
dexamethasone.
Trial Registration: clinicaltrials.gov Identifier: NCT02450968.
Keywords: chronic obstructive pulmonary disease, altitude, hypoxia, postural control, dexamethasone, acute
mountain sickness
INTRODUCTION
Today many settlements worldwide are located at high altitudes
(above 2500 m), with regular working places even above 3000 m.
Moreover, mountain tourism and air travel are increasingly
popular. Therefore, a large number of people, among them also
patients with respiratory conditions, are exposed to hypobaric
hypoxia. There are concerns that these patients may suffer
from altitude-related adverse health effects including impaired
postural control (PC), which may lead to falls or impaired
performance during various tasks with consecutive accidents. In
healthy individuals we have previously observed an impairment
in PC already at altitudes of 1630 and 2590 m (Stadelmann et al.,
2015). Other studies in healthy volunteers at a higher altitude
(Mount Rosa, 4559 m) and in hypobaric chambers (Holness et al.,
1982; Cymerman et al., 2001) have also demonstrated worsening
of PC. The underlying mechanisms are poorly understood
but it is presumed, that hypoxia affects different sensory
functions (visual, somatosensory and vestibular) as well as the
central nervous system that controls posture-regulating muscles
especially in the lower limbs and trunk within a few minutes
of exposure to altitudes of 2438 m (8000 ft) or higher (Wagner
et al., 2011; Chiba et al., 2016). During sojourns of more than a
few hours at high altitude PC may additionally be disturbed by
acute mountain sickness (AMS), which causes headache, ataxia,
weakness, dizziness, and decrements of alertness.
Chronic obstructive pulmonary disease (COPD) is associated
with chronic inflammation and obstruction of the airways,
parenchymal destruction of the lung with impaired gas exchange
that promotes hypoxemia and increased pulmonary artery
pressure (Vogelmeier et al., 2018). Given the high prevalence of
COPD, it is expected that many affected patients are undertaking
high altitude or air travel thereby suffering from impaired
PC, although this has not been specifically studied. Previous
observations suggest that elderly persons and patients with
COPD suffer from an impaired PC already at sea level (Muir et al.,
2010; Porto et al., 2015). Due to their pulmonary gas exchange
impairment COPD patients may have more severe hypoxemia
than healthy individuals at corresponding altitude. Thus, we
reasoned that COPD patients may experience pronounced PC
impairments during altitude or air travel with potentially grave
consequences such as dangerous falls, and that measures to
prevent or reduce this risk would be desirable.
The purpose of the current study was therefore twofold:
(1) to test the hypothesis that lowlanders with COPD would
experience impairments in PC during a stay at 3100 m and (2)
that these impairments could be prevented by treatment with
dexamethasone, a drug with potent glucocorticoid action. We
selected dexamethasone for this study because glucocorticoids are
used to treat COPD exacerbations and because it is effective in
prevention and treatment of AMS in healthy mountaineers.
MATERIALS AND METHODS
Study Design and Setting
The current study was performed from June to August
2015 within the scope of a randomized, placebo controlled
double blind parallel design trial evaluating effectiveness of
dexamethasone in prevention of altitude-related adverse health
effects (ARAHE) in lowlanders with COPD traveling to and
staying for 2 days at the high altitude (3100 m) clinic of Tuja-
Ashu, Kyrgyztan (clinicaltrials.gov Identifier: NCT02450968).
The effects of altitude and of dexamethasone on AMS and various
other clinical and physiologic outcomes have been reported
recently (Furian et al., 2018).
Participants
Men and women, aged 20–75 years, living in the Bishkek area
(Kyrgyz Republic, mean altitude 760 m) diagnosed with COPD
according to GOLD guidelines, grades 1–2, FEV1/FVC < 0.7
and FEV1 > 50% predicted were invited to participate. Exclusion
criteria were severe COPD with FEV1 < 50% predicted,
hypoxemia < 92% at 760 m measured by pulse oximetry, COPD
exacerbation, reversible airflow obstruction, a history suggesting
asthma or other respiratory disease, diabetes, uncontrolled
cardiovascular disease (such as systemic arterial hypertension,
coronary artery disease, previous stroke), history of obstructive
sleep apnea, pneumothorax in the last 2 months, untreated
or symptomatic peptic ulcer disease, or glaucoma and other
conditions that might have interfered with protocol compliance
including current heavy smoking (>20 cigarettes per day).
Participants gave written informed consent. The study was
approved by the Ethics Committee of the National Center
of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan(01-
8/405) and was endorsed by the Cantonal Ethics Committee
Zurich, Switzerland.
Interventions
Participants underwent baseline evaluation in Bishkek (760 m).
One to three weeks later, they travelled to the Tuja-Ashu high
altitude clinic (3100 m) by minibus within 3–5 h and stayed there
for 2 days. On the day before ascent and while staying at 3100 m,
participants took 4 mg capsules of oral dexamethasone twice
daily or identical looking placebo capsules under the supervision
of an investigator. During the study, participants continued
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their regular medication and no other treatment was allowed.
For safety reasons, participants with clinically relevant AMS
defined by an AMSc score ≥0.7 (see below), severe hypoxemia
(SpO2 < 75% for> 30 min, or< 70% for> 15 min), or any other
condition requiring an intervention according to the decision of
an independent physician were treated with supplemental oxygen
and other appropriate means.
Assessments
A medical history and clinical examination were obtained.
AMS was assessed by the environmental symptoms cerebral
score (AMSc) comprising 11 questions on AMS symptoms
each rated from 0 (not at all) to 5 (extreme) (Sampson et al.,
1983). The weighted sum of responses ranges from 0 to 5.
Scores ≥0.7 are considered to reflect clinically relevant AMS.
Pulse oximetry during rest (SpO2, Konica-Minolta PULSOX-
300i) and spirometry (EasyOne; NDD, Zurich, Switzerland) were
performed.
PC was assessed by a Wii Balance Board (WBB, Redmond,
WA, United States), 30 cm × 50 cm in size, as previously
described (Clark et al., 2010; Stadelmann et al., 2015).
Examinations took place at 760 m and on the second day of the
stay at 3100 m, within 20–26 h after arrival. The subjects stood on
the WBB on both legs with eyes open and feet positioned in a 30◦
angle, 20 cm apart. They were instructed to focus on a black dot
on the wall, 1.5 m in front of them at eye level, to keep their hands
beside the body and stand as still as possible during five tests each
lasting 30 s and separated by a resting period of 2–3 min. During
the tests, the WBB recorded displacements of the center of gravity
of the subject by 4 integrated sensors, using the sampling method
and filtering technique described in detail previously (Clark et al.,
2017). A customized software (Labview 8.5 National Instruments,
Austin, TX, United States) was used to calibrate the WBB with
standard weights and to compute the center of gravity path length
(COPL), and the mean and SD sway amplitude and velocity in the
antero-posterior (AP) and medio-lateral (ML) directions (Clark
et al., 2010; Holmes et al., 2013).
Outcomes and Sample Size Estimation
The main outcome was the center of pressure path length (COPL)
and additional outcomes were other variables from PC tests and
from clinical and physiological examinations including clinically
relevant AMS, severe hypoxemia, and other adverse effects that
required an intervention as mentioned above. Since the minimal
important difference for COPL and other indices of PC has
not been established we based the sample size estimation for
this study on previous studies in 51 healthy individuals who
showed a significant change in indices of PC measured by
the Wii balance board at 2590 m (Stadelmann et al., 2015).
In addition, a sample size estimation was performed for the
primary outcome of the main trial associated with the current
study, the cumulative incidence of ARAHE during the stay at
3100 m. According to these calculations, a minimal number of
100 participants including drop-outs were required to detect
a 50% reduction in ARAHE by dexamethasone (Furian et al.,
2018).
Randomization and Blinding
Participants were randomized 1:1 to dexamethasone or placebo
treatment by a computer algorithm minimizing for differences in
sex, age ≤ or > 50 years, FEV1 < or ≥ 80% predicted (Pocock
and Simon, 1975).
Study drugs were dispensed by an independent pharmacist in
sets of capsules labeled with a concealed code. Participants and
investigators were blinded to the assigned treatment until the
completion of data analysis.
Data Analysis
The primary data analysis was performed in the per protocol
population of participants who had successful evaluations at
both altitudes. In addition, an intention to treat analysis of the
main outcome, the COPL, was performed including data from all
randomized participants with missing data replaced by multiple
imputations. A separate analysis restricted to data from patients
>40 years of age was also performed excluding occasional
younger participants fulfilling spirometric criteria of COPD but
may not suffering from the classical form of the disease. To
reduce effects of measurement variability, mean results from the
five tests at each location are reported. Occasional individual
missing data in one of the five tests were replaced by group
medians of the corresponding altitude. Since most variables were
non-normally distributed, data are summarized by medians and
quartiles. Effect sizes were quantified by Cohen’s d (i.e., d = the
difference between two altitudes divided by the pooled standard);
with values of d < 0.2 considered small, 0.5 to 0.8, medium,
and > 0.8, strong (Cohen, 1977). The effects of altitude and of
the drug were evaluated by computing mean differences and 95%
confidence intervals (95% CI). Multivariable regression analysis
was performed with the COPL or AP sway velocity as dependent
variable and altitude or SpO2, dexamethasone, body height,
age, FEV1 (% predicted) and presence of AMS as independent
variables. A p-value< 0.05 was considered statistically significant.
RESULTS
A total of 118 patients with COPD fulfilled the inclusion criteria
and participated in the study (Figure 1). In 2 patients in the
dexamethasone group, balance tests at 3100 m could not be
performed because of AMS; in 12 additional patients, balance
tests were not available at both altitudes for various reasons.
Datasets from 104 patients who successfully underwent balance
tests at both locations could be included into the per protocol
analysis (Figure 1). Table 1 shows the demographic data of the
study participants. 70 of the 104 participants (67%) suffered from
mild airflow obstruction (GOLD grade 1) and 34 (33%) from
moderate airflow obstruction (GOLD grade 2); 97 participants
(93%) were >40 years old and 6 participants (7%) were <40
years old (31 to 38 years). 27 of the 118 patients (23%), 13 using
dexamethasone, 14 using placebo (P = 0.749, Chi-square statistic)
suffered from clinically relevant AMS, severe hypoxemia, or other
altitude-related adverse health effects.
With ascent from 760 to 3100 m the COPL increased
significantly in the placebo group from median (quartiles)
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FIGURE 1 | Study flowchart. 124 patients were randomized to dexamethasone respectively placebo. 6 patients were excluded after randomization leaving 118
patients in the intention to treat analysis. In 14 patients, successful balance tests were not available because of altitude-related adverse health effects (2) or
incomplete test series (12). 104 patients were included into the per protocol analysis.
29.2 cm (25.8; 38.2) to 31.5 cm (27.3; 39.3) (P < 0.05) but in the
dexamethasone group the corresponding increase from 28.8 cm
(22.8; 34.5) to 29.9 cm (25.2; 37.0) was not significant (P = 0.10)
(Table 2). An example of COPL recordings in a representative
individual is shown in Figure 2. Mean altitude-induced changes
in COPL are shown in Figure 3. The mean (95% CI) effect size
(Cohen’s d) of the altitude-induced COPL change in the placebo
group was d = 0.2 (0.02 to 0.39) and in the dexamethasone group
0.17 (−0.02 to 0.37).
Whereas the AP sway velocity increased significantly with
ascent to 3100 m in both groups, the medio-lateral sway velocity
did not change in any group. Dexamethasone had no significant
effect on any index of the PC. The mean difference between
dexamethasone and placebo groups in altitude-induced changes
in COPL (treatment effect) was −0.3 cm (95% CI −3.2 to 2.5)
(P = 0.41) (Figures 3, 4). The intention to treat analysis of the
COPL revealed similar results as the per protocol analysis: the
mean altitude-induced change in COPL in the placebo group
was 2.1 cm (95% CI 0.2 to 3.9, P = 0.028) in the dexamethasone
group the corresponding change was 1.8 cm (95% CI 0.01 to 3.7,
P = 0.049) and the treatment effect was−0.2 cm (95% CI−2.8 to
2.4, P = 0.869).
Multivariable regression analysis confirmed a significant
increase of 1.6 cm (0.2 to 3.1) [mean (95% CI)] in COPL and of
0.048 cm/s (0.009 to 0.087) in AP sway velocity when ascending
form 760 m to 3100 m but no decrease with dexamethasone when
controlled for several potential confounders (Tables 3, 4). The
mean (95% CI) effect size of the altitude-induced change adjusted
for potential confounders listed in Table 3 was d = 0.42 (0.36
to 0.48) in the placebo group and d = 0.49 (0.41 to 0.58) in the
dexamethasone group. Taking SpO2 instead of altitude as the
predictor in multivariable regression confirmed that hypoxemia
was associated with impaired PC: for each percentage point of
reduction in SpO2 the COPL was elongated by 0.3 cm (95% CI
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−0.5 to −0.05, P = 0.017) (Supplementary Table S1). A similar
negative correlation was found among SpO2 and AP sway
velocity (Supplementary Table S2).
Dexamethasone had no significant effect in the multivariable
regression on the COPL, AP- or ML-velocity (Tables 3, 4 and
Supplementary Tables S1, S2). However, age and body height
were associated with increased COPL and AP-velocity.
The presence or absence of AMS during the whole stay at
altitude had no significant influence on the COPL. However,
the movements in AP-direction, which are more influenced
by changes of altitude, were significantly increased in those
participants suffering from AMS (Supplementary Tables S2, S3).
In a regression analysis including the ten consecutive
performed tests (five tests at 760 m and the five at 3100 m) no
learning effect was observed (Supplementary Table S4).
TABLE 1 | Demographic data.
Placebo Dexamethasone
N 49 55
Sex, male/female 43/6 45/10
Age, years 60 (55; 64) 57 (51; 62)
GOLD grade I/II, n 36/13 34/21
FEV1, liters 2.7 (2.2; 2.9) 2.5 (1.9; 2.9)
FEV1, % predicted 96 (78; 108) 84 (70; 102)
FVC, liters 4.3 (3.7; 4.9) 4.1 (3.3; 4.5)
FVC, % predicted 121 (107; 137) 115 (98; 125)
FEV1/FVC 0.65 (0.6; 0.67) 0.63 (0.55; 0.66)
Cigarettes, pack years 25 (2; 38) 20 (0; 34)
BMI, kg/m2 24.8 (22.4; 26.8) 25.1 (23.1; 28.0)
Weight, kg 72 (65; 78) 71 (63; 80)
Height, m 1.70 (1.66; 1.75) 1.68 (1.63; 1.73)
SpO2 (760 m), % 95 (94; 96) 95 (94; 96)
SpO2 (3100 m), % 90 (88; 91) 90 (89; 92)
Medication
Inhaled bronchodilators, n (%) 2 (4%) 1 (2%)
Inhaled corticosteroids, n (%) 0 (0%) 0 (0%)
Antihypertensive drugs, n (%) 5 (10%) 7 (13%)
Beta-blocker, n (%) 3 (6%) 3 (5%)
Aspirin, n (%) 5 (10%) 5 (9%)
Antidiabetic drugs, n (%) 1 (2%) 0 (0%)
Values are shown in numbers or median (quartiles); FEV1 = Forced expiratory
volume in 1 second; FVC = Forced vital capacity; SpO2 = arterial oxygen saturation.
GOLD = Global Initiative for Chronic Obstructive Lung Disease.
Restricting the regression analysis to the 97 participants > 40
years old revealed similar results as those in Tables 3, 4 including
all 104 participants, i.e., there was a significant effect of altitude
on COPL and AP sway velocity but no significant effect of
dexamethasone (Supplementary Tables S5, S6).
DISCUSSION
We studied the effects of acute high altitude exposure (3100 m)
and of preventive dexamethasone treatment on postural control
(PC) in lowlanders with mild to moderate COPD (GOLD
grade 1 – 2). Our randomized, placebo controlled, double-
blind trial demonstrates that measures of PC, including AP
sway velocity and COPL increased at the higher altitude,
consistent with impaired PC during acute exposure to hypobaric
hypoxia. The results further revealed that the altitude-induced
postural instability was not prevented by treatment with
dexamethasone.
The current study is the first evaluating PC in lowlanders
with COPD ascending rapidly to high altitude. It is generally
assumed that the adverse effects of altitude exposure are related
to hypoxia in the nervous system and possibly muscles (Chiba
et al., 2016). Consistently, multiple regression analyses taking
several independent variables into account (dexamethasone, age,
sex, FEV1 in % predicted, body height) confirmed an independent
negative effect of SpO2 on COPL. Previous studies on PC in
various simulated and real altitudes have included small numbers
of mainly young, healthy volunteers and were conducted in
various settings, with different protocols and devices. In the
largest study, a randomized cross-over trial, performed in 51
healthy young men staying for 2 days each at 1630 and 2590 m
in the Alps, an altitude-related increase in COPL mainly due to
AP sway was observed (Stadelmann et al., 2015). Consistently, in
the current study, as well as in other previous studies, postural
stability was mainly impaired in the AP direction, while ML
sway was unchanged at altitude. Other studies using different
protocols and tests evaluated effects of much shorter exposures
to normobaric hypoxia (minutes to a few hours) at altitude
ranging from 2438 m to 5906 m and generally confirmed
impairment of PC.
In one study, sensomotoric, visual, and vestibular components
of hypoxia-induced impairment of PC were evaluated in
combination and separately by varying experimental conditions
such as visual inputs (eyes open/closed, sway-referenced visual
TABLE 2 | Center of pressure path length at 760 m and 3100 m with placebo and dexamethasone treatment.
Placebo Dexamethasone
760 m 3100 m 760 m 3100 m
Center of pressure path length, cm 29.2 (25.8; 38.2) 31.5∗ (27.3; 39.3) 28.8 (22.8; 34.5) 29.9 (25.2; 37.0)
Maximal AP amplitude, cm 2.362 (1.881; 2.806) 2.306 (2.083; 2.679) 2.535 (1.975; 3.113) 2.402 (1.848; 2.914)
AP velocity, cm/s 0.746 (0.645; 0.884) 0.797∗ (0.689; 1.030) 0.710 (0.570; 0.907) 0.760∗ (0.587; 1.011)
ML velocity, cm/s 0.500 (0.400; 0.665) 0.518 (0.469; 0.702) 0.509 (0.387; 0.598) 0.491 (0.413; 0.641)
Values are shown in median (quartiles); AP, antero-posterior; ML, medio-lateral; ∗p < 0.05 vs. baseline 760 m, paired Wilcoxon rank sum test.
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FIGURE 2 | Example of a center of pressure path in an individual COPD patient at 760 m (left) and at 3100 m (right). Measurement at 760 m and 3100 m: center of
pressure path length (COPL), 21.6 and 39.8 cm; antero-posterior sway velocity, 0.476 and 0.995 cm/s; medio-lateral sway velocity, 0.437 and 0.67 cm/s.
FIGURE 3 | Effect of altitude and of dexamethasone on the center of pressure path length. Altitude effect; difference between the center of pressure path length at
760 m and 3100 m; dexamethasone effect, difference of the altitude effect in the dexamethasone group minus the altitude effect in the placebo group. Mean values
and 95% confidence intervals of altitude-induced changes and of differences between dexamethasone and placebo are shown. ∗p-values < 0.05, ∗∗p < 0.01,
∗∗∗p < 0.001. Triangles represent raw values, circles represent values adjusted by multiple regression for age, height, weight, forced expiratory volume in 1 second
and acute mountain sickness score.
field), resting and moving platform. The results of these
investigations confirmed that static PC (eyes open) and reaction
time to unexpected movements of the platform were impaired
even during very short exposures of less than 1 h to altitudes
equivalent to 2438 m and 3048 m (Wagner et al., 2011).
While most previous studies were performed in young
volunteers between 21 and 56 years of age, Drum et al. (2016)
evaluated the combined mild normobaric hypoxia (altitude
equivalent 2600 m) and exercise (a 40 min treadmill walk) in
a group of 37 healthy seniors (mean ± SD age 62 ± 4 years).
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FIGURE 4 | Effect of the altitude and of dexamethasone on sway velocity in the (A) antero-posterior (AP) direction and (B) medio-lateral (ML) direction. Altitude
effect, difference between the center of pressure path length at 760 m and 3100 m; dexamethasone effect, difference of the altitude effect in the dexamethasone
group minus the altitude effect in the placebo group. Values are shown as mean (95% CI); ∗p < 0.05.
TABLE 3 | Effect of high altitude exposure on the center of pressure path length:
multivariable regression.
Dependent variable: Center of pressure path length, cm
R2 entire model = 0.180 P < 0.001 Coefficient 95% CI P-Value
Altitude (1 = 760 m; 2 = 3100 m) 1.6 0.2 to 3.1 0.031
Drug (1 = Plc; 2 = Dex) −0.2 −4.0 to 3.6 0.925
Age, years 0.4 0.2 to 0.6 0.001
Sex (1 = men; 2 = women) 1.1 −6.1 to 8.4 0.760
Height, cm 0.5 0.2 to 0.8 0.003
FEV1, % pred. −0.1 −0.2 to 0.0 0.082
AMS (1 = No; 2 = Yes) 3.4 −1.3 to 8.8 0.144
Intercept −61.7 −123.3 to −0.0 0.050
Plc, Placebo; Dex, Dexamethasone; FEV1, % pred., Forced expiratory volume in 1
second in % of the predicted FEV1; AMS, development of acute mountain sickness
during altitude exposure assessed by the environmental symptoms score ≥0.7.
Balance tests did not reveal an effect of simulated altitude at
rest but COPL were larger immediately after exercise at near sea
level conditions and even more so after exercise at simulated
altitude, suggesting a combined effect of muscular fatigue and
hypoxia on PC in these elderly individuals. The current study
confirms and extends these observations in a different setting
in COPD patients by demonstrating an independent negative
effect of altitude and older age on PC even at rest without
prior exercise (Tables 3, 4). Since COPD results from long-term
cumulative noxious exposures it is most commonly observed
in older individuals (>40 years). In the current study 7/104
(6%) participants were between 31 and 38 years old, an age that
is not typically compatible with the classical form of COPD.
We speculate that these individuals might have suffered from
infections and exposure to smoke and indoor air pollution
since early childhood. Such “disadvantage factors” may have
promoted irreversible airflow obstruction at a relatively young
age (Vogelmeier et al., 2018). Excluding data from participants
<40 years of age from analysis confirmed a robust effect of
altitude on PC in the 97 older COPD patients (>40 years old).
Since regression analysis of data in the current study
indicates that altitude as well as age and body height adversely
TABLE 4 | Effect of high altitude exposure on the antero-posterior sway velocity:
multivariable regression.
Dependent variable: AP sway velocity, cm/s
R2 entire model = 0.180 P < 0.001 Coefficient [95% CI] P-Value
Altitude (1 = 760 m; 2 = 3100 m) 0.048 0.009 to 0.087 0.016
Drug (1 = Plc; 2 = Dex) 0.006 −0.104 to 0.116 0.915
Age, years 0.011 0.004 to 0.018 0.001
Sex (1 = men; 2 = women) −0.037 −0.231 to 0.157 0.708
Height, cm 0.012 0.003 to 0.020 0.009
FEV1, % pred −0.003 −0.007 to 0.000 0.078
AMS (1 = No; 2 = Yes) 0.099 −0.014 to 0.212 0.085
Intercept −1.577 −3.385 to 0.230 0.087
Plc, Placebo; Dex, Dexamethasone; FEV1, % pred., Forced expiratory volume in 1
second in % of the predicted FEV1; AMS, development of acute mountain sickness
during altitude exposure assessed by the environmental symptoms score ≥0.7.
affects PC, it is important to take this into account when
assessing PC. Moreover, the study by Drum et al. (2016)
suggests that prior exercise may also affect PC, which may be
particularly relevant for older individuals desiring to hike in the
mountains.
Postural imbalance and ataxia are established diagnostic
criteria for severe AMS and high altitude cerebral edema
(HACE) (West, 1996; Hackett and Roach, 2004). The AMS
questionnaire includes items like “dizziness/lightheadedness”
or “my coordination is off” and the heel-to-toe walking as
elements related to postural balance (Sampson et al., 1983;
Sutton et al., 1992). However, studies on the relation among
postural instability at altitude and AMS are controversial.
Most studies could not show a relation between AMS and
PC (Baumgartner et al., 2002; Cymerman et al., 2001).
In the current investigation, multiple regression analysis
did not reveal consistent results. Whereas AMS was not
a significant predictor of the COPL, it was significantly
correlated with the AP-velocity and AP-amplitude. We cannot
exclude that the lack of a significant association between
COPL and AMS was related to the low prevalence of AMS
in our study. Further investigations are required to better
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define interactions among AMS and PC measured objectively
by a Wii balance board and other techniques in order to
determine clinically relevant changes in objective indices of PC
at high altitude and their relation to altitude-related illnesses
including AMS.
To date, data on prevention or treatment of impairment
in PC at altitude are scant. Baumgartner and coworkers
administered supplemental oxygen to volunteers at 4559 m but
failed to detect a beneficial effect on PC although symptoms
of AMS were reduced by the intervention (Baumgartner
and Bartsch, 2002). These authors therefore suggested that
postural ataxia at altitude resulted from different hypoxia-
dependent mechanisms than AMS. In the current study we
used dexamethasone to evaluate whether it might prevent
impairments in PC, AMS, and other altitude-related adverse
health effects such as insomnia and cognitive deficiencies in
COPD patients. The reason for the lack of a protective effect
of dexamethasone on PC remains unexplained. For safety
reasons, the study protocol required that all participants suffering
from clinically relevant AMS, severe hypoxemia or other
adverse health effects were treated with supplemental oxygen
and other appropriate means. These predefined precautions
may have introduced a “survivor effect” preventing the
observation of more severe PC impairments in the most
susceptible persons and, thus, obscuring a significant effect
of dexamethasone in the per protocol analysis. However, the
intention to treat analysis with replacement of missing data by
multiple imputation revealed similar altitude-induced changes
in COPL and confirmed absence of a significant effect of
dexamethasone thereby not supporting a relevant “survivor
effect”.
We cannot exclude that the applied dose of 2 mg × 4 mg
dexamethasone/day was insufficient to prevent altitude-induced
effects on PC. We selected this dose because it is recommended
for AMS prevention in current guidelines and was effective
in previous studies (Luks et al., 2014; Zheng et al., 2014).
We did not want to use a higher dose of dexamethasone
because of potential side effects including hypoglycemia. It
is also possible that the only mild impairment of PC we
found in the COPD patients reduced the sensitivity of our
trial to detect a significant reduction in the altitude-induced
impairment. The current results and those from previous
studies (Stadelmann et al., 2015) suggest that the Wii balance
board is a convenient technique to detect small to moderate
altitude-related effect sizes of PC changes under field conditions.
However, the accuracy of this simple and inexpensive tool
was inferior compared to a laboratory-grade force platform in
previous studies (Leach et al., 2014). Therefore, limitations in
our measurement technique may have concealed minor effects
of dexamethasone on PC even though we tried to minimize
instrument-related inaccuracies by repeated calibrations, and
by using the same board for all measurements in each
individual. Moreover, we computed mean values from five
tests in each individual in order to reduce variability in the
outcomes.
A limitation of our study is the lack of a healthy, age-
matched control group of Kyrgyz individuals, which would have
allowed to better assess the independent effect of COPD on
PC. The clinical relevance of the severity of PC impairment
observed in the current study is uncertain as we were unable
to correlate these findings directly to a clinical outcome. Kwok
and coworkers have shown that elderly individuals, 60–85 years
of age, with a greater (i.e., at the 75th percentile) baseline
AP sway velocity measured by a Wii balance board had an
approximately twofold greater risk of falls in the following year
compared to controls with less (i.e., at the 25th percentile)
postural sway at baseline. For comparison, 22 of the COPD
patients in this current study had an altitude-related increase in
the AP sway velocity of >25% – a change that was associated
with a twofold risk of falls in the cited study (Kwok et al., 2015).
Comparison of the current to the cited study is hampered by
differences in protocol and setting. Nevertheless, it is conceivable
that any measurable impairment of PC might increase the
risk of falls with potentially grave consequences for mountain
travelers.
CONCLUSION
This is the first study investigating PC in non-acclimatized
patients with mild to moderate COPD travelling from their
altitude of residence of around 760 m to a high altitude of 3100 m.
The main findings were an impairment of PC at altitude as
demonstrated by an increase in COPL and AP sway velocity.
Dexamethasone in a dose of 2 mg× 4 mg per day did not prevent
this impairment.
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